Arrowhead receives Health Canada authorisation for Redemplo to treat FCS [Yahoo! Finance]
Arrowhead Pharmaceuticals, Inc. (ARWR)
Last arrowhead pharmaceuticals, inc. earnings: 2/5 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.arrowheadpharma.com/investor-relations
Company Research
Source: Yahoo! Finance
an adjunct to diet for reducing triglycerides in adults with familial chylomicronemia syndrome (FCS) who have not responded to standard therapies. The approval provides a new treatment option for this rare condition, which is linked to extremely elevated triglyceride levels and an increased risk of acute, recurrent pancreatitis. Redemplo is said to be the first siRNA medicine approved by Health Canada for FCS and can be self-administered at home via subcutaneous injection every three months. This authorisation follows recent US approval. The therapy's approval was based on data from the Phase III PALISADE study, a placebo-controlled, randomised, double-blind trial involving adults with genetically or clinically confirmed FCS, at 39 sites globally, including five in Canada. Arrowhead Pharmaceuticals president and CEO Christopher Anzalone said: “We are thrilled to start the new year with Health Canada's approval of Redemplo as a new treatment option for Canadians living with gen
Show less
Read more
Impact Snapshot
Event Time:
ARWR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARWR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARWR alerts
High impacting Arrowhead Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ARWR
News
- Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its "overweight" rating reaffirmed by analysts at Piper Sandler. They now have a $110.00 price target on the stock, up previously from $100.00.MarketBeat
- Is Arrowhead Pharmaceuticals Stock a Buy or Sell After the CEO Sold Shares Worth $5.4 Million? [Yahoo! Finance]Yahoo! Finance
- Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After REDEMPLO Approvals And New Obesity Trial Data [Yahoo! Finance]Yahoo! Finance
- Arrowhead Pharmaceuticals Prices Offerings of Notes, Common Stock, Pre-Funded Warrants [Yahoo! Finance]Yahoo! Finance
- Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded WarrantsBusiness Wire
ARWR
Earnings
- 11/25/25 - Miss
ARWR
Sec Filings
- 1/12/26 - Form 8-K
- 1/9/26 - Form 8-K
- 1/9/26 - Form 424B5
- ARWR's page on the SEC website